JP6738285B2 - ヒト及びカニクイザルｃｄ３イプシロンに結合する抗体 - Google Patents

ヒト及びカニクイザルｃｄ３イプシロンに結合する抗体 Download PDF

Info

Publication number
JP6738285B2
JP6738285B2 JP2016569639A JP2016569639A JP6738285B2 JP 6738285 B2 JP6738285 B2 JP 6738285B2 JP 2016569639 A JP2016569639 A JP 2016569639A JP 2016569639 A JP2016569639 A JP 2016569639A JP 6738285 B2 JP6738285 B2 JP 6738285B2
Authority
JP
Japan
Prior art keywords
antibody
human
cells
seq
cynomolgus monkey
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016569639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516786A (ja
JP2017516786A5 (enExample
Inventor
ゲオルク ティーフェンタラー，
ゲオルク ティーフェンタラー，
エッケハルト メスナー，
エッケハルト メスナー，
ヴァレリア リフケ，
ヴァレリア リフケ，
ヨーゼフ プラッツァー，
ヨーゼフ プラッツァー，
ソニヤ オフナー，
ソニヤ オフナー，
クリスティアーネ イェーガー，
クリスティアーネ イェーガー，
ミルコ リッター，
ミルコ リッター，
Original Assignee
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2017516786A publication Critical patent/JP2017516786A/ja
Publication of JP2017516786A5 publication Critical patent/JP2017516786A5/ja
Application granted granted Critical
Publication of JP6738285B2 publication Critical patent/JP6738285B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016569639A 2014-05-28 2015-05-22 ヒト及びカニクイザルｃｄ３イプシロンに結合する抗体 Expired - Fee Related JP6738285B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14170140.9 2014-05-28
EP14170140 2014-05-28
EP14180572.1 2014-08-11
EP14180572 2014-08-11
PCT/EP2015/061457 WO2015181098A1 (en) 2014-05-28 2015-05-22 Antibodies binding to human and cynomolgus cd3 epsilon

Publications (3)

Publication Number Publication Date
JP2017516786A JP2017516786A (ja) 2017-06-22
JP2017516786A5 JP2017516786A5 (enExample) 2020-07-09
JP6738285B2 true JP6738285B2 (ja) 2020-08-12

Family

ID=53268799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016569639A Expired - Fee Related JP6738285B2 (ja) 2014-05-28 2015-05-22 ヒト及びカニクイザルｃｄ３イプシロンに結合する抗体

Country Status (13)

Country Link
US (3) US20170233475A1 (enExample)
EP (2) EP3149041A1 (enExample)
JP (1) JP6738285B2 (enExample)
KR (1) KR20170003591A (enExample)
CN (1) CN106459201A (enExample)
AU (1) AU2015266077A1 (enExample)
BR (1) BR112016022819A2 (enExample)
CA (1) CA2942453A1 (enExample)
IL (1) IL247740A0 (enExample)
MX (1) MX2016015389A (enExample)
RU (1) RU2016151235A (enExample)
SG (1) SG11201609950YA (enExample)
WO (1) WO2015181098A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL257696B2 (en) 2015-12-09 2024-11-01 Hoffmann La Roche Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
WO2017150762A1 (ko) * 2016-02-29 2017-09-08 (주)메디톡스 항-CD3γε 항체 및 이의 용도
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
AU2018276419A1 (en) 2016-06-02 2019-10-17 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
EP4606383A3 (en) * 2016-12-22 2025-12-17 Daiichi Sankyo Company, Limited Anti-cd3 antibody and molecules comprising the antibody
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
US11319371B2 (en) * 2017-06-05 2022-05-03 Numab Therapeutics AG Anti-CD3 antibodies
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
EA202090800A1 (ru) * 2017-09-21 2020-08-11 Уси Байолоджикс Аэлэнд Лимитед Новые анти-cd3-эпсилон антитела
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
JP7166342B2 (ja) 2017-11-30 2022-11-07 エフ．ホフマン－ラ ロシュ アーゲー Ｂ細胞培養法
JP7377590B2 (ja) 2018-03-14 2023-11-10 ノビミューン エスアー 抗ｃｄ３イプシロン抗体およびそれを使用する方法
RS66901B1 (sr) * 2018-05-24 2025-07-31 Janssen Biotech Inc Anti-cd3 antitela i njihova upotreba
US12129298B2 (en) 2018-06-21 2024-10-29 Daiichi Sankyo Company, Limited Compositions including CD3 antigen binding fragments and uses thereof
KR20230017841A (ko) * 2020-05-27 2023-02-06 얀센 바이오테크 인코포레이티드 Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
AU2021350342A1 (en) * 2020-09-24 2023-03-09 Morphosys Ag Novel human antibodies binding to human CD3 epsilon
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
TW202244059A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥
MX2023012408A (es) 2021-04-30 2023-10-31 Hoffmann La Roche Dosis para tratamiento conjunto con anticuerpo biespecifico anti-cd20/anti-cd3 y conjugado anticuerpo farmaco anti-cd79b.
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN113755435B (zh) * 2021-10-15 2023-10-13 苏州药明康德新药开发有限公司 一种食蟹猴pbmc分离方法
US20230295310A1 (en) * 2022-03-20 2023-09-21 Abcellera Biologics Inc. CD3 T-Cell Engagers and Methods of Use
AU2023240297A1 (en) * 2022-03-22 2024-10-03 Morphosys Ag Deimmunized antibodies specific for cd3
KR20240164782A (ko) 2022-03-23 2024-11-20 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체와 화학요법의 병용 치료
KR20250004776A (ko) 2022-04-13 2025-01-08 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체의 약학 조성물 및 사용 방법
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD272473B3 (de) * 1988-06-13 1993-01-21 Univ Leipzig Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten
JPH0630786A (ja) * 1992-07-14 1994-02-08 Kyowa Hakko Kogyo Co Ltd バイスペシフィック抗体
ES2526343T3 (es) * 2004-06-03 2015-01-09 Novimmune Sa Anticuerpos anti-CD3 y métodos de uso de los mismos
ES2856451T3 (es) * 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
SI2155788T1 (sl) * 2007-04-03 2012-11-30 Amgen Res Munich Gmbh Bispecifični vezavni element specifičen za križane vrste
EP2710042A2 (en) * 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
ME03440B (me) * 2011-05-21 2020-01-20 Macrogenics Inc Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
WO2015172800A1 (en) * 2014-05-12 2015-11-19 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules

Also Published As

Publication number Publication date
CN106459201A (zh) 2017-02-22
SG11201609950YA (en) 2016-12-29
RU2016151235A3 (enExample) 2019-01-18
AU2015266077A1 (en) 2016-09-29
IL247740A0 (en) 2016-11-30
KR20170003591A (ko) 2017-01-09
US20170233475A1 (en) 2017-08-17
CA2942453A1 (en) 2015-12-03
WO2015181098A1 (en) 2015-12-03
MX2016015389A (es) 2017-04-13
US20200299385A1 (en) 2020-09-24
EP3149041A1 (en) 2017-04-05
BR112016022819A2 (pt) 2018-01-16
JP2017516786A (ja) 2017-06-22
EP3763739A1 (en) 2021-01-13
RU2016151235A (ru) 2018-06-28
US20200325224A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
JP6738285B2 (ja) ヒト及びカニクイザルｃｄ３イプシロンに結合する抗体
JP7592050B2 (ja) 抗ｈｌａ－ｇ抗体とその使用
US20240270844A1 (en) Anti-tim3 antibodies and methods of use
US20230183349A1 (en) Anti-pd1 antibodies and methods of use
US20250051456A1 (en) Anti-hla-g antibodies and methods of use thereof
HK1231092A1 (en) Antibodies binding to human and cynomolgus cd3 epsilon
HK40044015A (en) Anti-hla-g antibodies and use thereof
HK1259019B (zh) 抗pd1抗体及使用方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200226

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20200526

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200717

R150 Certificate of patent or registration of utility model

Ref document number: 6738285

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees